4D Molecular Therapeutics (FDMT) FCF Margin: 2020-2025
Historic FCF Margin for 4D Molecular Therapeutics (FDMT) over the last 6 years, with Sep 2025 value amounting to -51,563.33%.
- 4D Molecular Therapeutics' FCF Margin rose 98740333.00% to -51,563.33% in Q3 2025 from the same period last year, while for Sep 2025 it was -154,209.17%, marking a year-over-year increase of 53260260.00%. This contributed to the annual value of -373,975.68% for FY2024, which is 37359657.00% down from last year.
- 4D Molecular Therapeutics' FCF Margin amounted to -51,563.33% in Q3 2025, which was up 82.20% from -289,620.00% recorded in Q2 2025.
- 4D Molecular Therapeutics' FCF Margin's 5-year high stood at 132,626.32% during Q4 2023, with a 5-year trough of -4,681,200.00% in Q4 2024.
- Over the past 3 years, 4D Molecular Therapeutics' median FCF Margin value was -106,421.43% (recorded in 2024), while the average stood at -637,445.61%.
- Per our database at Business Quant, 4D Molecular Therapeutics' FCF Margin plummeted by 481,382,632bps in 2024 and then surged by 98,740,333bps in 2025.
- 4D Molecular Therapeutics' FCF Margin (Quarterly) stood at -29,273.91% in 2021, then soared by 2,740,487bps to -1,869.05% in 2022, then surged by 13,449,536bps to 132,626.32% in 2023, then tumbled by 481,382,632bps to -4,681,200.00% in 2024, then skyrocketed by 98,740,333bps to -51,563.33% in 2025.
- Its FCF Margin stands at -51,563.33% for Q3 2025, versus -289,620.00% for Q2 2025 and -345,635.71% for Q1 2025.